Mechanism-based therapy for neuropathic pain-a concept in danger?

Affiliations

Editorial

Andreas Binder et al. Pain. 2015 Nov.

. 2015 Nov;156(11):2113-2114.

doi: 10.1097/j.pain.0000000000000334.

¹ Division of Neurological Pain Research and Therapy, Department of Neurology, Christian-Albrechts-Universität Kiel, Kiel, Germany.

No abstract available

Comment on

Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study.
Demant DT, Lund K, Finnerup NB, Vollert J, Maier C, Segerdahl MS, Jensen TS, Sindrup SH. Demant DT, et al. Pain. 2015 Nov;156(11):2234-2244. doi: 10.1097/j.pain.0000000000000266. Pain. 2015. PMID: 26090758 Clinical Trial.

1. Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? PAIN 2008;138:343–53.
1. Baron R, Förster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol 2012;11:999–1005.
1. Demant DT, Lund K, Finnerup NB, Vollert J, Maier C, Segerdahl MS, Jensen TS, Sindrup SH. Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype. A randomised, double-blind, and placebo-controlled phenotype panel study. PAIN 2015;156:2234–44.
1. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, Jensen TS, Sindrup SH. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. PAIN 2014;155:2263–73.
1. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain 2005;9:543–54.